MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
1.190
+0.020
+1.71%
After Hours: 1.240 +0.05 +4.20% 19:43 04/25 EDT
OPEN
1.190
PREV CLOSE
1.170
HIGH
1.225
LOW
1.140
VOLUME
1.63M
TURNOVER
0
52 WEEK HIGH
11.12
52 WEEK LOW
0.5902
MARKET CAP
84.40M
P/E (TTM)
-0.9389
1D
5D
1M
3M
1Y
5Y
Press Release: Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer. Dr. Manion brings over two decades of experience in pharmaceutical research and development. The company is targeting transcription factors to discover precision medicines for cancer and other diseases.
Dow Jones · 3d ago
ACLARIS THERAPEUTICS INC - MANION SUCCEEDS INTERIM CEO ABBIE CELNIKER WHO WILL CONTINUE TO SERVE AS CHAIR OF COMPANY'S BOARD OF DIRECTORS
Reuters · 3d ago
Weekly Report: what happened at ACRS last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at ACRS last week (0408-0412)?
Weekly Report · 04/15 09:11
Weekly Report: what happened at ACRS last week (0401-0405)?
Weekly Report · 04/08 09:12
Weekly Report: what happened at ACRS last week (0325-0329)?
Weekly Report · 04/01 09:12
Weekly Report: what happened at ACRS last week (0318-0322)?
Weekly Report · 03/25 09:12
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
TipRanks · 03/19 20:43
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.